Come visit the HematoLogics team at the 2019 ASH Meeting (Dec 7-10) in Orlando, FL. We will be located on Row 2100 and Booth 2164.
New FISH Probes added to the test menu:
TNFRSF14/ABL2: used in Pediatric-type Follicular Lymphoma
BLL-11q: used in Burkitt-like Lymphoma w/ 11 Aberration
DUSP22/IRF4 +Cen6: used in Large B-cell Lymphoma with IRF4 rearrangement
New HematoLogics Publication and the instrumental use of FACS FISH, provides the detection of BCR/ABL-1 positive T-cell lymphoblastic leukemia arising in early lymphoid progenitor cells and the possible treatment implications.
Click here to learn more
New Test Announcement: CD33, a new biomarker that determines response to Mylotarg therapy now available at HematoLogics.
Click here to learn more
HematoLogics in conjunction with Children’s Oncology Group discovered a new phenotype of Acute Myeloid Leukemia called RAM.
Click here to learn more
HematoLogics is the recognized leader for Measurable Residual Disease testing for Acute Leukemia. Click here to view the recently published data.
HematoLogics has increased the specificity of MYD88 L265P by 33% and the sensitivity of CXCR4 by 63% through Flow Cytometric Cell Sorting of Plasma and Lymphoid cells. Click to learn more.




Hematologics has assembled an in-house group of experts in each diagnostic field so that all testing is performed at Hematologics and not sent out to other specialty labs. This speeds up analysis and permits rapid response to unexpected findings due to communication between directors on every case.
Hematologics provides immunophenotyping, cytogenetics, fluorescence in situ hybridization, molecular analysis studies and microscopic examination in our own state-of-the-art flow cytometric, cytogenetic and molecular biology laboratories. Send us a sample, and we will provide full interpretive reports.